MCL
Haematology · 2016–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| acalabrutinib Previously untreated Stage III or IV mantle cell lymphoma in patients ineligible for autologous stem cell transplantation. | Jul 2025 | Recommended with restriction | input received Lymphoma Australia · Leukaemia Foundation · Rare Cancers Australia |
| acalabrutinib Treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least one prior therapy and have a WHO performance status of… | Jul 2021 | Recommended with restriction | input received Lymphoma Australia · Leukaemia Foundation · Rare Cancers Australia |
| zanubrutinib Treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least one prior therapy and have a WHO performance status of… | Jul 2021 | Recommended with restriction | input received Leukaemia Foundation · Lymphoma Australia · Rare Cancers Australia |
| ibrutinib Treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), and relapsed or refractory mantle cell lymphoma… | Nov 2020 | Recommended | input received Leukaemia Foundation |
| ibrutinib Relapsed or refractory mantle cell lymphoma (MCL); and first-line treatment of patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma… | Mar 2018 | Recommended with restriction | 2 individuals |
| ibrutinib Relapsed or refractory mantle cell lymphoma after at least one prior therapy. Proposed as monotherapy given as 560 mg (4 × 140 mg capsules) once daily until… | Nov 2017 | Not recommended | input received |
| lenalidomide Treatment of relapsed and/or refractory mantle cell lymphoma in adult patients who are unable to tolerate intensive chemotherapy or stem-cell transplantation,… | Jul 2016 | Not recommended | input received Lymphoma Group |
| ibrutinib Treatment of relapsed or refractory mantle cell lymphoma in patients who have received at least one prior therapy. | Nov 2016 | Not recommended | 21 individuals |
Who spoke
Leukaemia Foundation · Lymphoma Australia · Rare Cancers Australia · Lymphoma Group
What the PBS pays
$373M in government benefit over 2024–25, across 91,056 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| zanubrutinib | $136.4M |
| ibrutinib | $85.2M |
| lenalidomide | $78.7M |
| acalabrutinib | $72.9M |
Appraised elsewhere
NICE, in England and Wales, has appraised 6 technologies for this condition, recommending 4 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| zanubrutinibZanubrutinib for treating relapsed or refractory mantle cell lymphoma | TA1081 | recommended restricted | 2025-07 |
| lenalidomideLenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA774 | terminated | 2022-03 |
| brexucabtagene autoleucelBrexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma | TA677 | recommended restricted | 2021-02 |
| ibrutinibIbrutinib for treating relapsed or refractory mantle cell lymphoma | TA502 | recommended restricted | 2018-01 |
| bortezomibBortezomib for previously untreated mantle cell lymphoma | TA370 | recommended | 2015-12 |
| temsirolimusTemsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA207 | terminated | 2010-10 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| orelabrutinibHIBRUKA orelabrutinib 50 mg tablet bottle | 2026 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 8 of 8 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.